We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Silence Therapeutics Plc | LSE:SLN | London | Ordinary Share | GB00B9GTXM62 | ORD 5P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 535.00 | 521.00 | 524.00 | 0.00 | 01:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
0 | 0 | N/A | 0 |
TIDMSLN
RNS Number : 5801O
Silence Therapeutics PLC
02 October 2019
Director/PDMR Shareholding
October 2, 2019
LONDON, Silence Therapeutics, PLC (LON: SLN) ("Silence" or "the Company") a leader in the discovery, development and delivery of novel RNA therapeutics for the treatment of serious diseases, today announces that on October 2(nd) 10,000 Shares were purchased by Dr. Steven Romano, Non-Executive Director of the Company, at GBP1.93 per share.
Following this purchase, Dr. Steven Romano is interested in 10,000 ordinary shares (0.01%) of the issued shared capital of the Company.
Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them
1. Details of the person discharging managerial responsibilities (PDMR) / person closely associated a) Name Dr. Steven Romano --------------------------- -------------------------------------------- 2. Reason for the notification ------------------------------------------------------------------------- a) Position / status Non-Executive Director --------------------------- -------------------------------------------- b) Initial notification Initial notification / Amendment --------------------------- -------------------------------------------- 3. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor ------------------------------------------------------------------------- a) Name Silence Therapeutics plc --------------------------- -------------------------------------------- b) LEI 213800SSURRJBX85SQ91 --------------------------- -------------------------------------------- 4 Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted ------------------------------------------------------------------------- a) Description of Ordinary Shares of 5 pence each in Silence the financial instrument, Therapeutics plc type of instrument Identification code ISIN for Silence Therapeutics plc Ordinary Shares: GB00B9GTXM62 --------------------------- -------------------------------------------- b) Nature of the transaction Purchase of Ordinary Shares in Silence Therapeutics plc --------------------------- -------------------------------------------- c) Prices(a) and volume(s) Price Volume GBP1.93 10,000 ------- --------------------------- -------------------------------------------- d) Aggregated information - Aggregated volume 10,000 Ordinary Shares - Price GBP19,300.00 --------------------------- -------------------------------------------- e) Date of the transaction 02 October 2019 --------------------------- -------------------------------------------- f) Place of the transaction London Stock Exchange, AIM --------------------------- --------------------------------------------
Enquiries:
Silence Therapeutics plc Tel: +44 (0)20 3457 Dr David Horn Solomon, Chief Executive Officer 6900 Peel Hunt LLP (Nominated Adviser and Broker) Tel: +44 (0)20 7418 James Steel/Oliver Jackson 8900 European IR Tel: +44 (0) 20 Consilium Strategic Communications 3709 5700 Mary-Jane Elliott/Chris Welsh/Angela Gray silencetherapeutics@consilium-comms.com US IR Tel: +1 (443) 213-0505 Westwicke Partners Peter Vozzo peter.vozzo@westwicke.com
About Silence Therapeutics plc
Silence Therapeutics is developing a new generation of medicines by harnessing the body's natural
mechanism of RNA interference, or RNAi, within its cells. Its proprietary technology can selectively
inhibit any gene in the genome, specifically silencing the production of disease-causing proteins. Using
its enabling delivery systems, it has achieved an additional level of specificity by delivering its
therapeutic RNA molecules exclusively to target cells. Silence's proprietary RNA chemistries and
delivery systems are designed to improve the stability of our molecules and enhance effective delivery
to target cells, providing a powerful modular technology well suited to tackle life-threatening diseases.
For more information, please visit: https://www.silence-therapeutics.com/
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
END
DSHBLBDGRGGBGCD
(END) Dow Jones Newswires
October 02, 2019 12:09 ET (16:09 GMT)
1 Year Silence Therapeutics Chart |
1 Month Silence Therapeutics Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions